During 2025, Aclarion continued to build on its mission to transform the diagnosis of chronic low back pain achieving 69% year-over-year scan volume growth.

Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID. In October 2025, as announced, the company ...

Concerns about an increase in noise in the early hours of the morning have seen a McDonald’s blocked from opening earlier in ...

Solar panel reuse is emerging as a practical way to cut waste, extend system value, and make solar energy genuinely ...

Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced it has signed a definitive agreement to acquire Observe, a leader in AI-powered observability. With this acquisition, Snowflake will ...

HDFC Bank shares have fallen for five consecutive sessions, dropping 6% ahead of its Q3 earnings announcement. Technical ...

CERC seeks time to reply by Monday as the APTEL bench begins hearing. The shares of IEX gained over 1% after it slumped over ...

KARACHI: Shrugging off early volatility, the market extended its rally on Wednesday as investors continued to increase exposure across the board, propelling the benchmark KSE-100 index to an intraday ...

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company ...